Chlamydia trachomatis: ¿Co-factor o factor en el cáncer del cuello uterino?
Chlamydia trachomatis. Co-factor or factor in cancer of the cervix?
Resumen
El objetivo de este artículo fue revisar y analizar el posible papel que la Chlamydia trachomatis tiene como co-factor en el origen y desarrollo del cáncer del cuello uterino. Para dicho propósito, se revisó la bibliografía latino-americana e internacional en las bases de datos de Pub-Med, Google Scholar, Springer, la biblioteca Cochrane, Embase, Scielo, Imbiomed-L, Redalyc and Latindex. La búsqueda incluyó las palabras claves: Chlamydia trachomatis, epidemiología de la Chlamydia trachomatis, epidemiología del cáncer del cuello uterino, cáncer del cuello uterino, Chlamydia trachomatis e infección, Chlamydia trachomatis y mecanismo inflamatorios, cáncer del cuello uterino y co-factores, enfermedades de transmisión sexual y cáncer del cuello uterino, cáncer y mecanismos de la inflamación, carcinogénesis, mecanismos de la inflamación. Se revisaron y analizaron publicaciones desde 1970 hasta junio 2020. Este artículo de revisión analiza los posibles mecanismos que la Chlamydia trachomatis pudiera jugar en la carcinogénesis del cáncer del cuello uterino tanto como cofactor con el virus del papiloma humano o como factor independiente.
Descargas
Citas
O’Connell CM, Ferone ME. Chlamydia trachomatis genital Infections. Microb Cell. 2016;3(9):390-403.doi:10.15698/mic2016. 09.525.
BéBéar C, de Barbe B. Genital Chlamydia trachomatis infections. Clin Microbien Infect 2009:15(1):4-10.
Workowski KA, Bolan GA. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137. Erratum in: MMWR Recomm Rep 2015 Aug 28;64(33):924.
Rowley J, Vander Hoorn S, Korenromp E, Low N, Unemo M, Abu-Raddad LJ, Chico RM, Smolak A, Newman L, Gottlieb S, Thwin SS, Broutet N, Taylor MM. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 2019 1;97(8):548-562. doi: 10.2471/
BLT.18.228486. Epub 2019 Jun 6.
Redmond SM, Alexander-Kisslig K, Woodhall SC, van den Broek IVF, van Bergen J, Ward H, Uusküla A, Herrmann B, Andersen B, Götz HM, Sfetcu O, Low N. Genital chlamydia prevalence in European non-European high income countries: systematic review and meta-analysis. PLoS One 2015;10(1):e0115753. doi:10.1371/
journal.pone.0115753.
Núñez-Troconis J, Gallegos B, Noriega C. Incidencia de la Chlamydia trachomatis en pacientes con esterilidad. Invest. Clin 1990;31(2): 91-104.
Núñez-Troconis J. Investigación de tres patógenos de transmisión sexual en diferentes patologías ginecológicas. Rev Obstet Ginecol Venez 1998;58(3):175-185.
Vivas K, Albarracin L, Ruiz E, Téllez, Moreno Y, Noguera MU, Monsalve N, Mendoza JA. Infección por virus del papiloma humano y Chlamydia trachomatis y su implicación en el desarrollo de las lesiones cervicales en mujeres de la ciudad de Mérida. Rev Obstet Ginecol. 2018:78(2):113-121.
Albritton HL, Kozlowski PA, Lillis RA, McGowan Cl, Siren D, Taylor SN, Ibana JA, Buckner LR, Shen L, Quayle AJ. A novel whole bacterial enzyme linked immunosorbant assay to quantify Chlamydia trachomatis specific antibodies reveals distinct differences between systemic and genital compartments. PLoS One. 2017;12(8):e0183101. doi: 10.1371/journal.pone.0183101
Molano M, Weiderpass E, Posso H, Morré SA, Ronderos M, Franceschi S, Arsian A, Meijer CJLM, Miñoz N, van den Brule AJC, HPV study group. Prevalence and determinants of Chlamydia trachomatis infections in women from Bogota, Colombia. Sex Transm Infect. 2003;79(6):474-478. doi:10.1136/sti.79.6.474.
Malhotra M, Sood S, Mukherjee A, Muralidhar S, Bala M. Genital Chlamydia trachomatis: an update. Indian J Med Res. 2013 Sep;138(3):303-316. PMID: 24135174; PM- CID: PMC3818592.
Ward ME, Ridgway G. Chlamydia. In: Collier L, Balows A, Sussman A editors. Topley and Wilsons Microbiology and microbiology infection. 9th edition. New York Press Inc. 1999. p. 1331-1336.
Novak M, Novak D. Risk factors for Chlamydia trachomatis infection among users of an internet-based testing service in Sweeden. Sex Reprod Health 2013; 4: 23-27.
Stamm WE, Batteiger BE. Chlamydia trachomatis (Trachoma, Perinatal Infections, Lymphogranuloma Venerum and other Genital Infections). 7th edition. Mandell GL, Bennett JE, Dolin R, editors. Philadelphia: Churchill Livingstone Elsevier; 2010.
Wyrick PB. Chlamydia trachomatis persistence in vitro: An overview. J Infect Dis. 2010; 201 Suppl 2: S88–S95. Epub 2010 May 28.
Lambden PR, Pickett MA, Clarke IN. The effect of penicillin on Chlamydia trachomatis DNA replication. Microbiol 2006; 152(Pt 9): 2573- 2578.
Elwell C, Mirrashidi K, Engel J. Chlamydia cell biology and pathogenesis. Nat Rev Microbiol. 2016;14(6):385-400. doi: 10.1038/nrmicro.2016.30. Epub 2016 Apr 25. PMID:27108705; PMCID: PMC4886739.
Hussen S, Wachamo D, Yohannes Z, Tadesse E. Prevalence of Chlamydia trachomatis infection among reproductive age women in sub Saharan Africa: a systematic review and meta-analysis. BMC Infect Dis. 2018;18(1):596. doi:10.1186/s12879-018-3477.
Rogstad K. Complications in the female and their management. In: Moss T, ed. International handbook of Chlamydia, 3rd edition. Haslemere, UK: Alden Press, 2008; p. 111–121.
Peipert JF. Clinical practice. Genital chlamydial infections. N Engl J Med 2003; 349: 2424–2430.
Paavonen J, Eggert-Kruse W. Chlamydia trachomatis: impact on human reproduction. Hum Reprod Update 1999; 5: 433–447.
Hicks D. Complications of Chlamydia trachomatis infection in men. In: Moss TR, ed. International handbook of Chlamydia, 3rd edition. Haslemere, UK: Alden Press, 2008; p. 99–109.
Barbeyrac de B, Papaxanthos Roche A, Mathieu C, Germain C, Brun JL, Gachet M, Mayer G, Bébéar C, Chene G, Hock C. Chlamydia trachomatis in subfertile couples undergoing an in vitro fertilization program: a prospective study. Eur J Obstet Gynecol Reprod Biol 2006; 129: 46–53. PMID: 16701936 doi: 10.1016/j.ejo- grb.2006.02.014.
Malinverni R. The role of cytokines in chlamydial infections. Curr Opin Infect Dis 1996; 9: 150-155.
Morton RS, Kinghorn GR. Genitourinary chlamydial infection: a reappraisal and hypothesis. Int J STD AIDS 1999; 10 : 765-75.
Rasmussen SJ, Eckmann L, Quayle AJ, Shen L, Zhang Y, Anderson DJ, Fierer J, Stephens RS, Kagnoff MF. Secretion of pro-inflammatory cytokines by epithelial cells in response to Chlamydial infection suggests a central role for epithelial cells in chlamydial pathogenesis. J Clin Invest 1997; 99: 77-87.
Morrison SG, Morrison RP. A predominant role of antibody in acquired immunity to chlamydial genital tract reinfection. J Immunol 2005; 73: 6183-6186.
Haggerty CL, Gottlieb SL, Taylor BD, Low N, Xu F, Ness RB. Risk of sequelae after Chlamydia trachomatis genital infection in women. J Infect Dis 2010; 201 (Suppl 2): S134-S155.
Zdrodowska-Stefanow B, Ostaszewska-Puchalska I, Pucilo K. The immunology of Chlamydia trachomatis Arch Immunol Ther Exp 2003; 51: 289-294.
Burstein GR, Gaydos CA, Diener-West M. Incidence of Chlamydia trachomatis infection among inner-city adolescents. JAMA 1998; 280: 521-526.
Thompson PA, Khatami M, Baglole CJ, Sun J, Harris SA, Moon EY, Al-Mulla F, Al-Temaimi R, Brown DG, Colacci A, Mondello C, Raju J, Ryan EP, Woodrick J, Scovassi AI, Singh N, Vaccari M, Roy R, Forte S, Memeo L, Salem HK, Amedei A, Hamid RA, Lowe L, Guarnieri T, Bisson WH. Environmental immune disruptors, inflammation and cancer risk. Carcinogenesis. 2015;36(Suppl 1):S232-S253. doi: 10.1093/carcin/bgv038. PMID: 26106141; PMCID: PMC4492068.
Khatami, M. Chronic inflammation: synergistic interactions of recruiting macrophages (TAMs) and eosinophils (Eos) with host mast cells (MCs) and tumorigenesis in CALTs. M-CSF, suitable biomarker for cancer diagnosis! Cancers (Basel) 2014;6:297–322.
Colotta F, Allavena P, Sica A, Garlanda C, Mantivani A. Cancer related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009;30:1073–1081.
Hanahan, D, Weinberg RA. The hallmarks of cancer: the next generation. Cell 2000; 100:57–70.
Khatami, M. ’Yin and Yang’ in inflammation: duality in innate immune cell function and tumorigenesis. Expert Opin. Biol. Ther 2008;8:1461–1472.
Candido J, Hageman T. Cancer related inflammation. J. Clin. Immunol 2013;33 (suppl. 1): S79–S84.
Costa A, Scholer-Dahirel A, Mecha-Gregoriou F. The role of reactive oxygen speciesand metabolism on cancer cells and their microenvironment. Semin. Cancer Biol 2014;25: 23–32.
Khatami M. Unresolved inflammation: ‘immune tsunami’ or erosion of integrity in immune-privileged and immune-responsive tissues and acute and chroniinflammatory diseases or cancer. Expert Opin. Biol. Ther 2011;11:1419–1432.
Roberts RA, Smith RA, Safe S, Szabo C, Tjalkens RB, Robertson FM.. Toxicological and pathophysiological roles of reactive oxygen and nitrogen species. Toxicology 2010;276:85–94.
Naik E, Dixit VM. Mitochondrial reactive oxygen species drive proinflammatory cytokine production. J. Exp. Med 20111;208(3):417–420.
Kongara S, Karantza V. The interplay between autophagy and ROS in tumorigenesis. Front Oncol. 2012 Nov 21;2:171. doi: 10.3389/fonc.2012.00171. PMID: 23181220; PMCID: PMC3502876.
Danelli L, Frossi B, Sri G, Mion F, Guarnotta L, Tripodo C, Marluzzi L, Marzinotto S, Rigoni A, Blank U, Colombo MP, Pucillo CE. Mast cells boost myeloid derived suppressor cell activity and contribute to the development of tumor-favoring microenvironment. Cancer Immunol. Res. 2015;3(1):85–95. doi: 10.1158/2326-6066. CIR-14-0102. Epub 2014 Oct 28.
Grimm EA, Sikora AG, Ekmekcioglu S. Molecular pathways: inflammation associated nitric oxide production as a cancer supporting redox mechanism and a potential therapeutic target. Clin Cancer Res 2013;19(20):5557-5563. doi: 10. 1158/1078-0432.CCR-12-1554.
Moran EM. Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. J. Environ. Pathol. Toxicol. Oncol 2002;21:193–201.
Wakabayashi K. NSAIDs as cancer preventive agents. Asian Pac. J. Cancer Prev 2000:1:97–113.
Baglole CJ, Ray DM, Bernstein SH, Feldon SE, Smith TJ, Sime PJ, Phipps RP. More than structural cells, fibroblasts create and orchestrate the tumor microenvironment. Immunol. Invest. 2006;35(3-4):297-325. doi: 10.1080/08820130600754960.
Nataraj C, Thomas DW, Tilley SL, Nguyen MT, Mannon R, Koller BH, Coffman YM. Receptors for prostaglandin E2 that regulate cellular immune responses in the mouse. J. Clin. Invest. 2001;108(8):1229–1235. doi: 10.1172/JCI13640.
Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prosta glandins and thromboxanes. J Clin Invest 2001;108(1):15-23. doi:10.1172/JCI1341.
Zhu Z, Zhong S, Shen Z. Targeting the inflammatory pathways to enhance chemotherapy of cancer. Cancer Biol Ther 2011;12(2):95-105. doi:10.4161/cbt. 12.2.15952.
Bollrath J, Greten FR. IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep 2009;10(12):1314-1319. doi:10.1038/embor.2009.243.
Nguyen DP, Li J, Tewari AK. Inflammation and prostate cancer: the role of interleukin 6 (IL -6). BJU Int 2014;113(6):986-992. doi:10.1111/bju.12452.
Zhang HF, Lai R. STAT3 in Cancer Friend or Foe? Cancers (Basel) 2014;6(3):1408- 1440. doi:10.3390/cancers6031408.
He G, Karin M. NF-κB and STAT3 key players in liver inflammation and cancer. Cell Res 2011;21(1):159-168. doi:10.1038/cr.2010.183.
Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008; 223:7-19. doi:10.1111/ j.1600-065X.2008.00626.x
Croft M. The TNF family in T cell differentiation and function--unanswered questions and future directions. Semin Immunol 2014;26(3):183-190. doi:10.1016/j.smim. 2014.02.005.
Ataie-Kachoie P, Pourgholami MH, Richardson DR, Morris DL. Gene of the month: Interleukin 6 (IL -6). J Clin Pathol 2014;67(11):932-937. doi:10.1136 jclin- path-2014-202493.
Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006;80(2):227-236. doi:10.1189/jlb.1105674.
Taniguchi K, Karin M. IL 6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol 2014;26(1):54-74. doi:10.1016j. smim.2014.01.001.
Tsukamoto H, Nishikata R, Senju S, Nishimura Y. Myeloid derived suppressor cells attenuate TH1 development through IL -6 production to promote tumor progression. Cancer Immunol Res 2013;1(1):64- 76. doi:10.1158/2326-6066.CIR-13-0030.
Zarogoulidis P, Katsikogianni F, Tsiouda T, Sakkas A, Katsikogiannis N, Zarogoulidis K. Interleukin-8 and interleukin-17 for cancer. Cancer Invest 2014;32(5):197-205. doi: 10.3109/07357907.2014.898156.
Campbell LM, Maxwell PJ, Waugh DJ. Rationale and Means to Target Pro-Inflammatory Interleukin-8 (CXCL8) Signaling in Cancer. Pharmaceuticals (Basel) 2013; 6(8):929-59. doi: 10.3390/ph6080929. PMID: 24276377; PMCID: PMC3817732.
Schneider C, Pozzi A. Cyclooxygenases and lipoxygenases in cancer. Cancer Metastasis Rev 2011; 30(3-4):277-94. doi: 10.1007/ s10555-011-9310-3. PMID: 22002716; PM- CID: PMC3798028.
Greene ER, Huang S, Serhan CN, Panigrahy D. Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat 2011;96(1-4):27-36. doi: 10.1016/j.prostaglandins.2011.08.004. Epub 2011 Aug 16. PMID: 21864702; PM- CID: PMC4051344.
Bishayee K, Khuda-Bukhsh AR. 5-lipoxy-genase antagonist therapy: a new approach towards targeted cancer chemotherapy. Acta Biochim Biophys Sin (Shanghai). 2013;45(9):709-719. doi: 10.1093/abbs/
gmt064.
Gilmartin AG, Faith TH, Ritcher M, Groy A, Seefeld MA, Darcy MG, Peng X, Federowicz K, Yang J, Zhang SY, Minthon E, Jaworski JP, Schaber M, Marlens S, McNully DE, Sinnamon RH, Zhang H, Kirkpatrick RB, Nevins N, Cui G, Pietrak B, Diaz E, Jones A, Brandt M, Schwartz B, Heerding DA, Kumar R. Allosteric Wip1 phosphatase inhibition through flap subdomain interaction. Nat. Chem. Biol 2014;10(3):181-187. doi: 10.1038/nchembio.1427. Epub 2014 Jan 5.
Datta K, Biswal SS, Kehrer JP. The 5 lipoxygenase-activating protein (FLAP) inhibitor, MK886, induces apoptosis independently of FLAP. Biochem J 1999;340 (Pt 2) (Pt 2):371-375. PMID: 10333477; PMCID: PMC1220259.
Schuller HM, Zhang L, Weddle DL, Castonguay A, Walker K, Miller MS. The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK. J Cancer Res Clin Oncol 2002;128(10):525-532. doi:10.1007/ s00432-002-0365-y
International Agency for Research on Cancer. World Health Organization. Cancer 2018 Available at: https://gco.iarc.fr/ today/data/factsheets/populations/900- world-fact-sheets.pdf. Consulted on 06/20/2020.
Pan-American Health Organization. Cáncer Cervicouterino 2018. Available at: https:// www.paho.org/hq/index.php?option=com_ content&view=article&id=5420:2018- cervical-cancer&Itemid=3637&lang=es. Consultred on: 06/20/2020.
Smith JS, Bosetti C, Munoz N, Herrero R, Bosch FX, Eluf-Neto J, Meijer CJ, Van Den Brule AJ, Franceschi S, Peeling RW. Chlamydia trachomatis and invasive cervical cancer: A pooled analysis of the IARC multicentric case-control study. Int J Cancer 2004;111: 431–439.
Schachter J, Hill EC, King EB, Coleman VR, Jones P, Meyer KF. Chlamydial infection in women with cervical dysplasia. Am J Obstet Gynecol 1975;123:753–757.
Silins I, Ryd W, Strand A, Wadell G, Tomberg S, Hansson BG, Wang X, Arnheim L, Dahl L, Dahl V, Brenell D, Parson K, Diener J, Rylander E. Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer 2005;116(1):110- 115. doi:10.1002/ijc.20970.
Murta EFC, de Souza MAH, Adad SJ, Araújo Jr E. Infecção pelo papilomavírus humano em adolescentes: relação com o método anticoncepcional, gravidez, fumo e achados citológicos. Rev Bras Ginecol Obstet 2001;23: 217-221.
Martins MCL, Bôer CG, Svidzinski TIE, Estivalet TI, Donida LG, Martins PFA, Boscoli FNS, Consolaro MEL. Avaliação do método de Papanicolaou para triagem de algumas infecções cérvico-vaginais. Rev Bras Anal Clin 2007;39: 217-221.
Campos ACC, Freitas-Júnior R, Ribeiro LFJ, Paulinelli RR, Reis C. Prevalence of vulvovaginitis and bacterial vaginosis in patients with koilocytosis. Sao Paulo Med J 2008;126: 333-336.
Wohlmeister D, Vianna DR, Helfer VE, Gimenes F, Consolaro ME, Barcellos RB, Rossetti ML, Calil LN, Buffon A, Pilger DA. Association of human papillomavirus and Chlamydia trachomatis with intraepithelial alterations in cervix samples. Mem Inst Oswaldo Cruz 2016 Feb;111(2):106- 113. doi: 10.1590/0074-02760150330. Epub 2016 Feb 2. PMID: 26841046; PM- CID: PMC4750450.
Muvunyi CM, Dhont N, Verhelst R, Crucitti T, Reijans M, Mulders B, Simons G, Temmerman M, Claeys G, Padalko E. Evaluation of a new multiplex polymerase chain reaction assay STDFinder for the simultaneous detection of 7 sexually transmitted disease pathogens. Diagn Microbiol Infect Dis 2011; 71: 29-37.
Rodríguez-Cerdeira C, Sánchez-Blanco E, Alba A. Evaluation of association between vaginal infections and high-risk human papillomavirus types in female sex workers in Spain. ISRN Obstet Gynecol 2012: 240190. doi:10.5402/2012/240190.
Reddy BS, Rastogi S, Das B, Salhan S, Verma S, Mittal A. Cytokine expression pattern in the genital tract of Chlamydia trachomatis positive infertile women implication for T-cell responses. Clin Exp Immunol 2004;137(3):552-558. doi:10.1111/ j.1365-2249.2004.02564.x
Pal S, Hui W, Peterson EM, de la Maza LM. Factors influencing the induction of infertility in a mouse model of Chlamydia trachomatis ascending genital tract infection. J Med Microbiol 1998; 47:599–605.
Brunham RC. Human immunity to chlamydiae. In: Stephens RS, ed. Chlamydia: Intracellular Biology, Pathogenesis and Immunity. Washington DC: ASM Press, 1999; 211–238.
Igietseme JU, Uriri IM, Kumar SN, Anaqnaba GA, Ojior OO, Momodu IA, Caudal DH, Black CM. Route of infection that induces a high intensity of gamma interferon secreting T-cells in the genital tract produces optimal protection against Chlamydia trachomatis infection in mice. Infect Immun 1998; 66:4030–4035.
Kelly KA, Robinson E, Rank RG. Initial route of antigen administration alters the T-cell cytokine profile produced in response to the mouse pneumonitis biovar of Chlamydia trachomatis following genital infection. Infect Immun 1996; 64:4976–4983.
Kelly KA 2, Walker JC, Jameel SH, Gray HL, Rank RG. Differential regulation of CD4 lymphocyte recruitment between the upper and lower regions of the genital tract during Chlamydia trachomatis infection. Infect Immun 2000; 68:1519–1528.
Rank RG, Bowlin AK, Kelly KA. Characterization of lymphocyte response in the female genital tract during ascending chlamydial genital infection in the guinea pig model. Infect Immun 2000; 68:5293–5298.
Openshaw P, Murphy EE, Hosken NA, Maine V, Davis K, Murphy K, O’Garra. Heterogeneity of intracellular cytokine synthesis at the single cell level in polarized T helper 1 and T helper 2 populations. J Exp Med 1995; 182:1357–1367.
Arno JN, Ricker VA, Batteiger BE. Interferong in endocervical secretions of women infected with Chlamydia trachomatis. J Infect Dis 1990; 162:1385–1389.
Rank RG, Ramsey KH, Pack EA, Williams DM. Effect of gamma interferon on resolution of murine chlamydial genital infection. Infect Immun 1992; 60:4427–4429.
Zhong G, Peterson EM, Czarniecki CW, Schreiber RD, de la Maza LM. Role of endogenous gamma interferon in host defense against Chlamydia trachomatis infections. Infect Immun 1989; 57:152–157.
Perry LL, Feilzer K, Caldwell HD. Immunity to Chlamydia trachomatis is mediated by T-helper 1 cells through IFN gamma dependent and independent pathways. J Immunol 1997; 158:3344–3352.
Beatty WL, Byrne GI, Morrison RP. Morphologic and antigenic characterization of interferon gamma mediated persistent Chlamydia trachomatis infection in vitro. Proc Natl Acad Sci USA 1993; 90:3998– 4002.
Rottenberg ME, Gigliotti-Rothfuchs A, Wigzell H. The role of IFN gamma in the outcome of chlamydial infection. Curr Opin Immunol 2002; 14:444–451.
Durum SK, Schimidt JA, Oppenheim JJ. Interleukin-1: An immunological perspective. Ann Rev Immunol 1985; 3:263–287.
MittalA,KapurS,GuptaS. Host Immuneresponse in chlamydial cervicitis. Br J Biomed Sci 1996; 53:941–947.
Kelly KA. Cellular immunity and Chlamydia genital infection: Induction, recruitment and effector mechanisms. Int Rev Immunol 2003; 22:3–41. doi: 10.1080/08830180305229.
Tseng CK, Rank RG. Role of NK cells in early host immune response to chlamydial genital infection. Infect Immun 1998; 66:5867–5875.
Stagg AJ, Elsley WAJ, Holland MJ. Dendritic cells (DC) in the initiation of immune responses to Chlamydia. In: Mardh PA, La Placa M, Ward ME, eds. Proceedings Of European Society for Chlamydia Research. Town: Publisher, 1992: p.77–80.
Conti P, Kempuraj D, Kandere K, Di Gioacchino M, Barbacane RC, Castellani ML, Felaco M, Bouchr W, Letourneau R, Theoharides TC. IL 10, an inflammatory/ inhibitory cytokine, but not always. Immunol Lett 2003; 86:123–129. doi: 10.1016/ s0165-2478(03)00002-6.
Campbell K. Understanding how viruses can cause malignant disease. Nurs Times 2006; 102:30-31.
Campbell K. The infectious causes of cancer. Nurs Times 2006;102:28-30.
Ledwaba T, Dlamini Z, Naicker S, Bhoola K. Molecular genetics of human cervical cancer: role of papillomavirus and the apoptotic cascade. Biol Chem 2004;385:671- 682.
Nahar A, Azad AK. Sexually transmitted diseases (STD) / reproductive tract infections (RTI) including acquired immunodeficiency syndrome (AIDS) / human immunodeficiency virus (HIV) infections among the women of reproductive age group: a review. J Prev Soc Med 1999;18:84-88.
Thomas DJ. Sexually transmitted viral infections: epidemiology and treatment. J Obstet Gynecol Neonatal Nurs 2001;30:316- 323.
Kanodia S, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets 2007;7:79-89.
Klein E, Kis LL and Takahara M. Pathogenesis of Epstein-Barr virus (EBV)-carrying lymphomas. Acta Microbiol Immunol Hung 2006;53:441- 457.
Negro F. Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J Gastroenterol 2006;12:6756-6765.
Moss SF, Blaser MJ. Mechanisms of disease: Inflammation and the origins of cancer. Nat Clin Pract Oncol 2005;2:90-97.
Rapp F. Current knowledge of mechanisms of viral carcinogenesis. Crit Rev Toxicol 1984; 13:197-204.
Rogstad K. Complications in the female and their management. In: Moss T, ed. International handbook of Chlamydia, 3rd edition. Haslemere, UK: Alden Press, 2008; p. 111–121.
Gilden RV, Rabin H. Mechanisms of viral tumorigenesis. Adv Virus Res 1982;27:281-334.
Cuschieri KS, Horne AW, Szarewski A, Cubie HA. Public awareness of human papillomavirus. J Med Screen 2006;13:201- 207.
Behtash N, Mehrdad N. Cervical cancer: screening and prevention. Asian Pac J Cancer Prev 2006;7:683-686.
Dehn D, Torkko KC, Shroyer KR. Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma. Cancer 2007;111:1-14.
Weaver BA. Epidemiology and natural history of genital human papillomavirus infection. J Am Osteopath Assoc 2006;106:S2-8.
Zheng ZM, Baker CC. Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci 2006; 11:2286-2302.
Monsonego J. Cervical cancer prevention: the impact of HPV vaccination. Gynecol Obstet Fertil 2006;34:189-201.
Malik AI. The role of human papilloma virus (HPV) in the aetiology of cervical cancer. J Pak Med Assoc 2005;55:553-558.
Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine 2006;24:S1-1S5.
González-Martinez G, Núñez-Troconis J. Historia natural de la infección por el virus del papiloma humano: una actualización. Invest Clin 2014;55(1):82-91
Lehtinen M, Ault KA, Lyytikainen E, Dillner J, Garland SM, Ferris DG, Koutsky LA, Sings HL, Lu S, Haupt RM, Paavonen J; FUTURE I and II Study Group. Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect 2011 Aug;87(5):372-6. doi: 10.1136/ sti.2010.044354. Epub 2011 Apr 6. PMID: 21471141; PMCID: PMC3252607.
Madeleine MM, Anttila T, Schwartz SM, Saikku P, Leinonen M, Carter JJ, Wurscher M, Johnson LG, Galloway DA, Daling JR. Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors. Int J Cancer 2007;120(3):650-655. doi: 10.1002/ijc.22325. PMID: 17096345; PM- CID: PMC4049152.
Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah K, Snijders PJF, Meijer CJLM, International Agency for Research on Cancer, Mukticenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348(6):518-527. doi:10.1056/NEJMoa021641.
Gravitt PE, Castle PE. Chlamydia trachomatis and cervical squamous cell carcinoma. JAMA 2001;285:1703-1704.
Al-Daraji WI, Smith JH. Infection and cervical neoplasia: facts and fiction. Int J Clin Exp Pathol 2009;2(1):48-64.
Fullgrabe J, Kavanagh E, Joseph B. Histone onco modifications. Oncogene 2011;30: 3391–3403.
Clayton AL, Mahadevan LC. MAP kinasemediated phosphoacetylation of histone H3 and inducible gene regulation. FEBS Lett 2003;546, 51–58.
Chumduri C, Gurumurthy RK, Zadora PK, Mi Y, Meyer TF. Chlamydia infection promotes host DNA damage and proliferation but impairs the DNA damage response. Cell Host Microbe 2013;13(6):746-758. doi:10.1016/j.chom.2013.05.010
Pennini ME, Perrinet S, Dautry-Varsat A, Subtil A. Histone methylation by NUE, a novel nuclear effector of the intracellular pathogen Chlamydia trachomatis. PLoS Pathog 2010;6, e1000995.
Miller KM, Jackson SP. Histone marks: repairing DNA breaks within the context of chromatin. Biochem. Soc. Trans 2012; 40: 370–376.
O’Driscoll M, Jeggo A. The role of double strand break repair insights from human genetics. Nat. Rev. Genet 2006;7: 45–54.
Lebreton A, Lakisic G, Job V, Fritsch L, Tham TN, Camejo A, Matteı PJ, Regnault B, Nahori MA, Cabanes D, Gautreau A, Ait-Si Ali S, Dessen A, Cossart P, Bierne H. A bacterial protein targets the BAHD1 chromatin complex to stimulate type III interferon response. Science 2001; 331:1319–1321.
Fehri LF, Rechner C, Janssen S, Mak TN, Holland C, Bartfeld S, Bruggemann H, Meyer FM. Helicobacter pylori induced modification of the histone H3 phosphorylation status in gastric epithelial cells reflects its impact on cell cycle regulation. Epigenetics 2009; 4: 577–586.
Fernandez-Capetillo O, Allis CD, Nussenzweig A. Phosphorylation of histone H2B at DNA double-strand breaks. J. Exp. Med 2004; 199:1671–1677.
Utley RT, Lacoste N, Jobin-Robitaille O, Allard S, Coté J. Regulation of NuA4 histone acetyltransferase activity in transcription and DNA repair by phosphorylation of histone H4. Mol. Cell. Biol 2005;25: 8179–8190.
Tjeertes JV, Miller KM, Jackson SP. Screen for DNA-damage responsive histone modifications identifies H3K9Ac and H3K56Ac in human cells. EMBO J 2009;28;1878–1889.
Paavonen J, Purola E. Cytologic findings in cervical chlamydial infection. Med Biol 1980;58(3):174-178.
Luostarinen T, Lehtinen M, Bjorge T, Abeler V, Hakana M, Hellman’s G, Jellum E, Koskela T, Lenner P, Lie AK, Paavonen J, Pukkala E, Saikku P, Sigstad E, Thoresen S, Thoresen S, Yuongman LD, Diller J, Hakulinen T. Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamouscell carcinoma of the cervix uteri. Eur J Cancer 2004;40:1058e65.
Arnheim L. Immunological Responses in Genital HPV Infections and Etiology of Cervical Cancer. Stockholm, Sweden: Karolinska Institute, 2005:1e75. Available http:// diss. kib.ki.se/2005/91-7140-266-7/thesis. pdf. Accesed on: June 10, 2020.
Quint KD, de Koning MN, Geraets DT, Quint WG, Pirog EC. Comprehensive analysis of Human Papillomavirus and Chlamydia trachomatis in insitu and invasive cervical adenocarcinoma. Gynecol Oncol 2009;114(3):390-394. doi:10.1016/j.ygy- no.2009.05.013
Agrawal T, Vats V, Wallace L. Role of cervical dendritic cell subsets, co-stimulatory molecules, cytokine secretion profile and beta estradiol in development of sequalae to Chlamydia trachomatis infection. BMC Reproduct Biol Endocrinol 2008;6:46.
Samoff E, Koumans EH, Markowitz LE, Sternberg M, Sawyer MK, Swan D, Papp JR, Black CM, Unger ER. Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. Am J Epidemiol 2005;162(7):668-675. doi: 10.1093/aje/kwi262. Epub 2005 Aug 24.
Stamm WE. Chlamydia trachomatis infections of the adult. In: Holmes KK, Mardh PA, Sparlin PF, Lemon SM, Stamm WE, Piot P, Wasserheit JN, editors. Sexually transmitted diseases, 3rd edition. New York: McGraw-Hill, 1999. p:407–422.
Nobbenhuis MA, Walboomers JM, Helmer-horst TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999; 354:20–25.
Kjaer SK, van den Brule AJ, Paull G, Svare EI, Sherman ME, Thomsen BL, Suntum M, Bock JE, Poll PA, Meijer CJ. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002; 325:572.
Schiffman M, Solomon D. Cervical-cancer screening with human papillomavirus and cytologic co-testing. New Engl J Med 2013;369: 2324-2331.
Martins MCL, Bôer CG, Svidzinski TIE, Estivalet TI, Donida LG, Martins PFA, Boscoli FNS, Consolaro MEL. Avaliação do método de Papanicolaou para triagem de algumas infecções cérvico-vaginais. Rev Bras Anal Clin 2007;39: 217-221.
Campos ACC, Freitas-Júnior R, Ribeiro LFJ, Paulinelli RR, Reis C. Prevalence of vulvovaginitis and bacterial vaginosis in patients with koilocytosis. Sao Paulo Med J 2008;126: 333-336.
Muvunyi CM, Dhont N, Verhelst R, Crucitti T, Reijans M, Mulders B, Simons G, Temmerman M, Claeys G, Padalko E. Evaluation of a new multiplex polymerase chain reaction assay STDFinder for the simultaneous detection of 7 sexually transmitted disease pathogens. Diagn Microbiol Infect Dis 2011;71: 29-37.
Schachter J, Hill EC, King EB, Coleman VR, Jones P, Meyer KF. Chlamydial infection in women with cervical dysplasia. Am J Obstet Gynecol 1975;123:753–757.
Smith JS, Bosetti C, Munoz N, Herrero R, Bosch FX, Eluf-Neto J, Meijer CJ, Van Den Brule AJ, Franceschi S, Peeling RW. Chlamydia trachomatis and invasive cervical cancer: A pooled analysis of the IARC multicentric case-control study. Int J Cancer 2004;111: 431–439.
Hakama M, Lehtinen M, Knekt P, Aromaa A, Leinikki P, Miettinen A, Paavonen J, Peto R, Teppo L. Serum antibodies and subsequent cervical neoplasms: a prospective study with 12 years of follow-up. Am J Epidemiol 1993;137:166–170.
Anttila T, Saikku P, Koskela P, Bloigu A, Dillner J, Ikaheimo I, Jellum E, Lehtinen M, Lenner P, Hakulinen T, Narvanen A, Pukkala E, Thoresen S, Youngman L, Paavonen J. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 2001;285:47–51. doi: 10.1001/jama.285.1.47.
Wallin KL, Wiklund F, Luostarinen T, Angstrom T, Anttila T, Bergman F, Hallmans G, Ikaheimo I, Koskela P, Lehtinen M, Stendahl U, Paavonen J, Diener J. A population based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int J Cancer 2002; 101:371–374. doi: 10.1002/ijc.10639.
Koskela P, Anttila T, Bjørge T, Brunsvig A, Dillner J, Hakama M, Hakulinen T, Jellum M, Lethinen M, Lenner P, Luos-Tarinen T, Pukkala, Saikku E, Thoresen S, Youngman J, Paavonen J. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer. 2000; 85:35–39. doi: 10.1002/ (sici)1097-0215(20000101)85:1<35::aidijc6>3.0.co;2-a.
Quint KD, de Koning MN, Geraets DT, Quint WG, Pirog EC. Comprehensive analysis of Human Papillomavirus and Chlamydia trachomatis in in situ and invasive cervical adenocarcinoma. Gynecol Oncol 2009;114(3):390-394. doi:10.1016/j. ygyno.2009.05.013.
Ghosh I, Mandal R, Kundu P, Biswas J. Association of genital infections other than human papillomavirus with pre-Invasive and invasive cervical neoplasia. J Clin Diagn Res. 2016 Feb;10(2):XE01-XE06. doi: 10.7860/JCDR/2016/15305.7173. Epub 2016 Feb1.
Johnston VJ, Mabey DC. Global epidemiology and control of Trichomonas vaginalis. Curr Opin Infect Dis 2008;21(1):56-64. doi:10.1097/QCO.0b013e3282f3d999
Paavonen J. Chlamydia trachomatis and cancer. Sex Transm Infect 2001; 77: 154-156.
Deluca GD, Basiletti J, Schelover E, Díaz- Vásquez N, Alonso JM, Marin HM, Lucero RH, Picconi MA. Chlamydia trachomatis as a probable cofactor in human papillomavirus infection in aboriginal women from northeastern Argentina. Braz J Infect Dis 2011;15(6):567-572. doi:10.1016/s1413-8670(11)70252-5.
Gopalkrishna V, Aggarwal N, Malhotra VL, Koranne RV, Mohan VP, Mittal A, Das BC. Chlamydia trachomatis and human papillomavirus infection in Indian women with sexually transmitted diseases and cervical precancerous and cancerous lesions. Clin Microbiol Infect 2000;6(2):88-93. doi:10.1046/j.1469-0691.2000.00024.x
Verhoeven V, Baay M, Weyler J, Avonts D, Lardon F, Van Royen P, Vermorken JB. Concomitant Chlamydia trachomatis and human papilloma virus infection cannot be attributed solely to sexual behavior. Eur J Clin Microbiol Infect Dis 2004;23(9):735- 737.
Smith JS, Muñoz N, Herrero R, Eluf-Neto J, Ngelangle C, Francheschi S, Bosch FX, Walboomers JMM, Peeling RW. Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J Infect Dis 2002;185(3):324-331. doi:10.1086/338569.
Fan T, Lu H, Hu H,Shi L, McCarty GA, Nance DM, Greenberg AH, Zhong G. Inhibition of apoptosis in chlamydia-infected cells: blockade of mitochondrial cytochrome c release and caspase activation. J Exp Med 1998;187:487–496.
Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide–dependent mechanism. Cancer Res 2000;60: 184–190.
Zhu H, Shen Z, Luo H, Zhang W, Zhu X. Chlamydia Trachomatis Infection-Associated Risk of Cervical Cancer: A Meta-Analysis. Medicine (Baltimore). 2016;95(13):e3077. doi:10.1097/MD.0000000000003077.
Velicer C, Zhu X, Vuocolo S, Liaw KL, Saah A. Prevalence and incidence of HPV genital infection in women. Sex Transm Dis. 2009;36(11):696-703. doi:10.1097/ OLQ.0b013e3181ad25ff
Shew ML, Fortenberry JD, Tu W, Juliar BE, Batteiger BE, Qadadri B, Brown DR. Association of condom use, sexual behaviors, and sexually transmitted infections with the duration of genital human papillomavirus infection among adolescent women. Arch Pediatr Adolesc Med 2006;160(2):151-156. doi: 10.1001/archpedi.160.2.151.
Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, DeRouen TA, Galloway DA, Veton D, Kivat NB. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992;327(18):1272-1278. doi:10.1056/NEJM199210293271804.
Lehtinen M, Dillner J, Knekt P, Luostarinen T, Aromaa A, Kirnbauer R, Koskela P, Paavonen J, Peto R, Schiller JT, Hakama M. Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study. BMJ 1996;312(7030):537-539. doi: 10.1136/ bmj.312.7030.537.
Naucler P, Chen HC, Persson K, You SL, Hsieh CY, Sun CA, Dillner J, Chen CJ. Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: nested case control study. J Gen Virol 2007;88(Pt 3):814-822. doi:10.1099/vir.0.82503-0.
Anttila T, Saikku P, Koskela P, Bloigu A, Dillner J, Ikaheimo I, Jellum E, Mehtinen M, Lenner P, Hakulinen T, Narvanen A, Pukkala E, Thoresen S, Youngman L, Paavonwn J.. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 2001;285(1):47-51. doi:10.1001/jama.285.1.47.
Workowski KA, Suchland RJ, Pettinger MB, Stamm WE. Association of genital infection with specific Chlamydia trachomatis serovars and race. J Infect Dis 1992; 166:1445-1449.
Kuo CC, Wang SP, Holmes KK, Grayston T. Immunotypes of Chlamydia trachomatis isolates in Seattle, Washington. Infect Immun 1983;41:865-868.
Saikku P, Wang SP. Chlamydia trachomatis immunotypes in Finland. APMIS 1987;95:131-134.
Moncan T, Eb F, Orfila J. Monoclonal antibodies in serovar determination of 53 Chlamydia trachomatis isolates from Amiens, France. Res Microbiol 1990; 141:695-701.
Barnes RC, Rompalo AM, Stamm WE. Comparison of Chlamydia trachomatis serovars causing rectal and cervical infections. J Infect Dis 1987;156:953-958.
Poole E, Lamont I. Chlamydia trachomatis serovar differentiation by direct sequence of the variable segment 4 region of the major outer membrane protein gene. Infect Immun 1992; 60:1089-1094.
Barnes RC, Suchland RJ, Wang S P, Kuo CC, Stamm WE. Detection of multiple serovars of Chlamydia trachomatis in genital infections. J Infect Dis 1985;152:985- 989.
Fan T, Lu H, Hu H, McCarty GA, Nance DM, Greenberg AH, Zhong G. Inhibition of apoptosis in chlamydia-infected cells: blockade of mitochondrial cytochrome c release and caspase activation. J Exp Med 1998;187(4):487- 496. doi:10.1084/jem.187.4.487.
